PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-35.03%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-37.55%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-34.88%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-34.88%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
2.03%
Share count expansion well above AXSM's 0.34%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.03%
Diluted share count expanding well above AXSM's 0.34%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
9.65%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.42%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
54.54%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
-31.27%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
85.15%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
56.20%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
-42.46%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-24.53%
Negative equity/share CAGR over 10 years while AXSM stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.00%
Negative 5Y equity/share growth while AXSM is at 283.63%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-54.63%
Negative 3Y equity/share growth while AXSM is at 53.57%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Negative asset growth while AXSM invests at 57.16%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.07%
We have a declining book value while AXSM shows 148.52%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-5.00%
We’re deleveraging while AXSM stands at 25.04%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
41.18%
R&D growth drastically higher vs. AXSM's 15.67%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
22.12%
SG&A growth well above AXSM's 6.39%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.